12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 06/12/2024 16:31
Gainers
- Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million.
- vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million.
- Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion.
- Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million.
- Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million.
- Autonomix Medical (NASDAQ:AMIX) stock rose 20.94% to $1.42. The market value of their outstanding shares is at $26.6 million.
Losers
- ThermoGenesis Holdings (NASDAQ:THMO) shares fell 31.4% to $0.38 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million.
- TRACON Pharma (NASDAQ:TCON) shares decreased by 25.92% to $0.8. The company's market cap stands at $2.1 million.
- Streamline Health Solns (NASDAQ:STRM) shares declined by 21.86% to $0.5. The market value of their outstanding shares is at $31.0 million. As per the news, the Q1 earnings report came out yesterday.
- Nanoviricides (AMEX:NNVC) stock fell 21.76% to $2.59. The market value of their outstanding shares is at $30.5 million.
- Calidi Biotherapeutics (AMEX:CLDI) shares fell 16.67% to $0.23. The market value of their outstanding shares is at $14.4 million.
- Avinger (NASDAQ:AVGR) stock declined by 16.16% to $1.61. The company's market cap stands at $2.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.